Status:
COMPLETED
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Bipolar I Disorder
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
Eligibility Criteria
Inclusion
- Male or female patients 18 to 65 years of age (inclusive)
- Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type as per DSM-V criteria
- Symptomatically stable within the past two months
Exclusion
- Exposure to any investigational medication, including placebo, in the past 60 days
- Non-response to clozapine
Key Trial Info
Start Date :
October 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 27 2019
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04127058
Start Date
October 7 2019
End Date
November 27 2019
Last Update
April 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Marlton, New Jersey, United States, 08009